ArticleBMC pregnancy and childbirth2020
Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Article in BMC pregnancy and childbirth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 90 citations in OpenAlex.
- Article
- Species Distribution ofPathogens (Basel, Switzerland) · 2026Article
- Non-albicans Candida vaginal infections in sub-Saharan Africa: a systematic review, meta-analysis, and narrative synthesis of prevalence, antifungal resistance, and clinical implications among women of reproductive age.Tropical medicine and health · 2026Review
- From Identification to Resistance: Contemporary Insights into Candida Species Causing Vaginitis.Cureus · 2026Review
- Vulvovaginal candidiasis and antifungal susceptibility pattern of isolated Candida spp. among women in Aden Governorate, Yemen.BMC infectious diseases · 2026Article
- Isolation of non-albicans Candida and associated factors among symptomatic women presenting with abnormal vaginal discharge at Mubende Regional Referral Hospital, Central Uganda: A cross-sectional study.PLOS global public health · 2026Article
- Development of Novel Approaches for the Treatment of Cutaneous Candidiasis.Current pharmaceutical design · 2026Review
- Article
- Occurrence of Multidrug-Resistant Candidiasis Among Pregnant Women at a Peri-Urban Hospital, Uganda.Cureus · 2025Article
- Aetiology of Vulvovaginal Candidiasis in Ecuador and In Vitro Antifungal Activity AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Candidiasis knowledge, Self-Reported infection history, preventive practices, and associated factors among female tertiary students in Ghana.BMC women's health · 2025Article
- Antifungal susceptibility profiles ofMicrobiology spectrum · 2025Article
- Prevalence of urinary tract infections and antibiotic susceptibility patterns of bacterial isolates in first-time ANC attendees at a secondary health facility in Ghana: a cross-sectional study.BMC pregnancy and childbirth · 2025Article
- The prevalence and risk factors of vaginal Candida species and group B Streptococcus colonization in pregnant women attending antenatal care at Hawassa university comprehensive specialized hospital in Hawassa City, Southern Ethiopia.BMC pregnancy and childbirth · 2025Article
- Vulvovaginal candidiasis: knowledge, practices and occurrence among pregnant women receiving antenatal care in a teaching hospital, Ghana.Frontiers in global women's health · 2025Article
- New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.Frontiers in microbiology · 2025Review
- Resistant C. albicans implicated in recurrent vulvovaginal candidiasis (RVVC) among women in a tertiary healthcare facility in Kumasi, Ghana.BMC women's health · 2024Article
- Review
- Antifungal susceptibility pattern ofFrontiers in cellular and infection microbiology · 2024Article
- The Formulation and Evaluation ofGels (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida is the leading cause of vaginitis, and 75% of women have at least one episode of infection in their lives, with pregnancy being a predisposing factor. If left untreated, vulvovaginal candidiasis (VVC) can lead to chorioamnionitis with subsequent abortion, prematurity and congenital infection of the neonate. We aimed to determine the prevalence of VVC, identify the recent and most frequently occurring species of Candida in pregnant women, and determine the most effective antifungal drug of choice for treatment.
methodA prospective cross-sectional study in which 176 high vaginal swab samples of consented pregnant women visiting the antenatal clinic from February 2018 to April 2018 were subjected to direct gram smear and culture for Candida isolation. Candida isolates were identified using a germ tube test and HiCrome Candida differential agar. Candida isolates were then subjected to a disk diffusion method using fluconazole (25 μg), nystatin (100 units), and voriconazole (1 μg) on Mueller-Hinton agar supplemented with 2% (w/v) glucose and 0.5 μg/ml methylene blue dye to determine the susceptibility pattern as per the guidelines of the Clinical Laboratory Standard Institute (CLSI). Chi-square analysis was used to ascertain the significant association of participants' sociodemographics and clinical presentations to VVC. A univariate logistic regression model was used to identify potential risk factors of VVC.
resultsThe prevalence of VVC among our study participants was 30.7%. Non-albicans Candida (NAC) and Candida albicans had a prevalence of 74.1 and 25.9%, respectively. Candida glabrata was the most common species, followed by Candida albicans, Candida krusei, and Candida parapsilosis. 50.0, 18.5 and 3.7% of Candida species were susceptible to voriconazole, fluconazole and nystatin, respectively, whereas 37.0, 48.1 and 9.3% of Candida species were resistant to voriconazole, fluconazole and nystatin, respectively. The majority of isolates were susceptible dose dependent to all three antifungal agents, with voriconazole being the most efficacious antifungal agent. There was no significant association between participants' socio-demographic information and clinical presentations to VVC.
conclusionThe prevalence of VVC was high in the study area. C. glabrata was found to be the most common cause of VVC among the pregnant women attending antenatal clinics, in the Ho Municipality region of Ghana. The majority of the Candida isolates were susceptible and resistant to voriconazole and fluconazole, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.